glucophage filmuhúðuð tafla 500 mg
merck santé s.a.s.* - metforminum hýdróklóríð - filmuhúðuð tafla - 500 mg
abstral tungurótartafla 800 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 800 míkróg
abstral tungurótartafla 600 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 600 míkróg
abstral tungurótartafla 400 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg
abstral tungurótartafla 300 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 300 míkróg
abstral tungurótartafla 200 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 200 míkróg
abstral tungurótartafla 100 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 100 míkróg
midazolam accord stungulyf/innrennslislyf, lausn 5 mg/ml
accord healthcare b.v. - midazolamum hýdróklóríð - stungulyf/innrennslislyf, lausn - 5 mg/ml
midazolam accord stungulyf/innrennslislyf, lausn 1 mg/ml
accord healthcare b.v. - midazolamum hýdróklóríð - stungulyf/innrennslislyf, lausn - 1 mg/ml
pylclari
curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).